Genmab — Juni 2025

[E_L]

only Time to Treatment Discontinuation Due to AE is new. (the other was already there, the old 5. ) to me the question is more; why wasn't that there in the first place (logical measure)

[lahn1]

Yes as 4-1BB has a history of poor tolerability, it seems logical to be able to show durable tolerability with zero or low discontinuation rates. Docetaxel having 15-20% discontinuation as SOC in 2L NSCLC.

[E_L]

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer https://investors.biontech.de/news-releases/news-release-details/biontech-announces-strategic-transaction-acquire-curevac-public

[Solsen]

I belive Genmab still have some shares left i CureVac.

[E_L]

they may have, but for a relatively small value. If I remember correct, they invested $20mn and sold a part of that for +-$60mn (?) . The remainder collapsed in value...

[E_L]

Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma https://www.ajmc.com/view/epcoritamab-improves-outcomes-hrqol-in-patients-with-relapsed-refractory-follicular-lymphoma EHA 2025

[gentogen]

Thanks EL for the link 15:24 yesterday. Pure KYSO...

[Helge_LarsenPI-redaktør]

Oversigt: Ny udgave af ØU Life Science – Genmab accelererer mod blockbusterstatus med Rina-S efter data
https://proinvestor.com/investornyt/1328695/oversigt-ny-udgave-af-ou-life-science-genmab-accelererer-mod-blockbusterstatus-med-rina-s-efter-data

[Helge_LarsenPI-redaktør]

(Artiklen om Genmab kræver ikke abonnement)

[Budweis]

Ser lovende ud https://ml-eu.globenewswire.com/Resource/Download/0b2cf0bd-906b-4985-b4ad-f7d8b772b972

[Budweis]

Genmab Announces Epcoritamab Investigational Combination Therapy
Demonstrates High Response Rates in Patients with Relapsed or
Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for
Autologous Stem Cell Transplantation (ASCT)

[JKY_VH]

Super og mange tak for den Budweis:-)

[Bulder]

Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.

[E_L]

Lymphoma Hub
@lymphomahub
CONGRESS | #EHA2025 | PRESENTATION
Daniel Kerr,
@TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5
trial (N = 37). https://x.com/lymphomahub/status/1934185493723263388

[E_L]

"These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.

[Helge_LarsenPI-redaktør]

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) https://proinvestor.com/investornyt/1329270/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-trans

[Solsen]

[Solsen]

https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.

[E_L]

Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html

[E_L]

sry that's the same one lol